{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:35:55Z","timestamp":1791653755249,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.vaccine.2004.12.023","type":"journal-article","created":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T04:16:30Z","timestamp":1106712990000},"page":"3139-3147","source":"Crossref","is-referenced-by-count":73,"title":["Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus"],"prefix":"10.1016","volume":"23","author":[{"given":"Douglas S.","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen M.","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Lackemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2004.12.023_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0042-6822(92)90190-Z","article-title":"Phylogenetic analysis of alphaviruses in the Venezuelan equine encephalitis complex and identification of the source of epizootic viruses","volume":"191","author":"Weaver","year":"1992","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2004.12.023_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0891-5520(20)30389-5","article-title":"Arboviral infections in the United States","volume":"5","author":"Tsai","year":"1991","journal-title":"Infect Dis Clin North Am"},{"issue":"9","key":"10.1016\/j.vaccine.2004.12.023_bib3","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/JVI.71.9.6697-6705.1997","article-title":"Repeated emergence of epidemic\/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus","volume":"71","author":"Powers","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.12.023_bib4","unstructured":"Smith JF, Davis K, Hart MK, Ludwig GV, McClain DJ, Parker MD, et al. Viral encephalitides. In: Sidwell RW, Takafuji ET, Franz DR, editors. Medical aspects of chemical and biological warfare, vol. I. Washington, DC: Office of the Surgeon General; 1997, p. 561\u201390."},{"issue":"4","key":"10.1016\/j.vaccine.2004.12.023_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2004.12.023_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0264-410X(96)00204-6","article-title":"Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB\/c, but not C3H\/HeN mice","volume":"15","author":"Hart","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.12.023_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutations of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2004.12.023_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.2001.64.49","article-title":"Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice","volume":"64","author":"Ludwig","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"26","key":"10.1016\/j.vaccine.2004.12.023_bib9","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/S0264-410X(00)00042-6","article-title":"Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate","volume":"18","author":"Hart","year":"2000","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2004.12.023_bib10","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2004.12.023_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4269\/ajtmh.1998.59.100","article-title":"Association of Venezuelan equine encephalitis virus subtype IE with two equine epizootics in Mexico","volume":"59","author":"Oberste","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2004.12.023_bib12","unstructured":"Franck PT. Discussion: round table on epidemic control. In: Proceedings of the Workshop-Symposium on Venezuelan Equine Encephalitis Virus, vol. 243. Washington, DC: Pan American Health Organization; 14\u201317 September 1971; p. 400."},{"issue":"2","key":"10.1016\/j.vaccine.2004.12.023_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4269\/ajtmh.1979.28.329","article-title":"Ten clinical cases of human infection with venezuelan equine encephalomyelitis virus, subtype I-D","volume":"28","author":"Dietz","year":"1979","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2004.12.023_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4269\/ajtmh.1965.14.475","article-title":"Two human cases of laboratory infection with Mucambo virus","volume":"14","author":"De Mucha-Macias","year":"1965","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2004.12.023_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1086\/382281","article-title":"Aerosol infection of cynomolgus macaques with enzootic strains of Venezuelan equine encephalitis viruses","volume":"189","author":"Reed","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2004.12.023_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0264-410X(01)00337-1","article-title":"Onset and duration of protective immunity to IA\/B and IE strains of Venezuelan equine encephalitis virus in vaccinated mice","volume":"20","author":"Hart","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.12.023_bib17","unstructured":"Parker MD, Crise B, Oberste S, Lind CM, Smith JF, Hart MK. Attenuation of enzootic VEE by furin cleavage site deletion of a full length cDNA clone, manuscript in preparation."},{"issue":"4","key":"10.1016\/j.vaccine.2004.12.023_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4269\/ajtmh.1970.19.703","article-title":"Discovery and geographic distribution of Venezuelan encephalitis virus in Guatemala, Honduras, and British Honduras during 1965\u201368, and its possible movement to Central America and Mexico","volume":"19","author":"Scherer","year":"1970","journal-title":"Am J Trop Med Hyg"},{"issue":"910","key":"10.1016\/j.vaccine.2004.12.023_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0264-410X(97)00192-8","article-title":"Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates","volume":"16","author":"Pratt","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.12.023_bib20","first-page":"55","article-title":"Recombinant Vaccinia-Venezuelan equine encephalomyelitis (VEE) vaccine protects nonhuman primates against parenteral and intranasal challenge with virulent VEE virus","volume":"1","author":"Monath","year":"1992","journal-title":"Vaccine Res"},{"issue":"9","key":"10.1016\/j.vaccine.2004.12.023_bib21","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1128\/JVI.74.9.4258-4263.2000","article-title":"The use of chimeric Venezuelan equine encephalitis viruses as an approach for the molecular identification of natural virulence determinants","volume":"74","author":"Powers","year":"2000","journal-title":"J Virol"},{"issue":"5861","key":"10.1016\/j.vaccine.2004.12.023_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/297070a0","article-title":"Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis","volume":"297","author":"Schmaljohn","year":"1982","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2004.12.023_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0168-1702(02)00275-7","article-title":"Cytotoxic T-cell activity is not detectable in Venezuelan equine encephalitis virus-infected mice","volume":"91","author":"Jones","year":"2003","journal-title":"Virus Res"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2004.12.023_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0165-5728(02)00108-X","article-title":"Contribution of T cells to mortality in neurovirulent Sindbis virus encephalomyelitis","volume":"127","author":"Rowell","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2004.12.023_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-065X.1997.tb01013.x","article-title":"The role of antibody in recovery from alphavirus encephalitis","volume":"159","author":"Griffin","year":"1997","journal-title":"Immunol Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T08:37:01Z","timestamp":1625387821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0264410X05001015"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.12.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}